Skip to main navigation
  • Sustainability
  • Email Alerts
  • Contact Us
  • Language
    • English
    • 简体中文
    • 繁體中文
Zailab Logo Zailab Logo
  • Investor 
    Overview
  • Stock 
    Information
    • Stock Quote & Chart
    • Historical Lookup
    • Analyst Coverage
  • Corporate 
    Governance
    • Documents & Charters
    • Committee Composition
  • Events & 
    Presentations
    • Event Calendar
    • Webcasts & Presentations
    • Shareholder Meetings
  • Financials 
    & Filings
    • SEC Filings
    • HKEX Announcements & Notices
    • Annual Reports
  • Investor 
    Resources
    • Investor FAQ
    • Information Request
    • Investor & Media Contacts
  • News & 
    Media
    • Press Releases
    • Partner News
  • Search
  • Sustainability
  • Email Alerts
  • Contact Us
  • Language
    • English
    • 简体中文
    • 繁體中文

Press Release

Partner News
Oct 25, 2019

MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer

MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer 116.7 KB
Zai Lab Footer Logo
Copyright @ 2024 Zai Lab All Rights Reserved.
Contact Us
Top Main